Hence, targeted anti-HER2 therapy for HER2+ breast cancer is inadequate treatment—it must still be combined with chemotherapy, despite HER2 amplification being identified as an oncogenic driver [45,46,47]. The gene discussed is ERBB2; the disease is breast carcinoma.